secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2026-07-17T01:50:00+00:00
Accession:  0001213900-26-078887
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.01, 5.03, 2.01, 3.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics acquires Kira Pharmaceuticals; issues ~9.8M shares and raises $132M PIPE
--------------------------------------------------------------------------------

- Jasper issued ~5.2M common shares and ~4.6M convertible preferred shares to Kira shareholders; Kira holders own ~88.73% of pro forma common pre-PIPE.
- Concurrent $132M PIPE from sale of ~4.7M preferred shares (convertible into 61 common each) to new investors; closing expected July 20, 2026.
- Pre-merger Jasper shareholders receive one CVR per share entitling to pro rata share of $30M if FDA issues Priority Review Voucher for briquilimab by Dec 31, 2028.
- Kira subsidiary entered Mirador License Agreement for anti-C5a assets; $12M upfront, up to $458.5M milestones, low-to-mid single-digit royalties.
- Board changes: Vishal Kapoor and Scott Brun resigned; Patrick Crutcher appointed director; Matthew Ros appointed COO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390026078887/0001213900-26-078887-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390026078887/ea0298229-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-078887

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer